Ticagrelor was associated with a significantly higher 1-year myocardial infarction risk compared to clopidogrel and prasugrel in patients with coronary stent restenosis.
Does ticagrelor alter the 1-year risk of myocardial infarction compared to clopidogrel and prasugrel in patients with coronary stent restenosis?
Patients with coronary stent restenosis
Ticagrelor prescription
Clopidogrel and prasugrel prescription
1-year myocardial infarction (MI) riskhard clinical
In a real-world cohort of patients with coronary stent restenosis, ticagrelor was associated with a significantly higher 1-year risk of myocardial infarction compared to clopidogrel and prasugrel.
In this real-world cohort of patients with coronary stent restenosis, ticagrelor was associated with a significantly higher 1-year MI risk compared to clopidogrel and prasugrel. These findings suggest potential differences in clinical outcomes among P2Y12 inhibitors in this high-risk setting and highlight the need for further prospective investigation to confirm these results.
Building similarity graph...
Analyzing shared references across papers
Loading...
Yesh Dhruva
Akhil V Kumar
Atman K Shah
Heart & Lung
Saint Louis University
Saint Louis University Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Dhruva et al. (Sun,) reported a other. Ticagrelor was associated with a significantly higher 1-year myocardial infarction risk compared to clopidogrel and prasugrel in patients with coronary stent restenosis.
www.synapsesocial.com/papers/69a91cbed6127c7a504bfa2b — DOI: https://doi.org/10.1016/j.hrtlng.2026.102752
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: